CD8A and neoplasm: Our previous studies demonstrated that tumors can induce PD-L1 expression in BECs, inhibit the infiltration and activity of CD8+ T cells within tumor tissues, and increase the infiltration of FoxP3+ T cells, while anlotinib can inhibit tumor growth by downregulating PD-L1 expression in tumor BECs, thereby removing or weakening this immune barrier (13).